Astellas Pharma raises full-year earnings forecast on strong strategic brand sales

Astellas Pharma Inc. is revising its consolidated financial forecasts for the fiscal year ending March 31, 2026 (FY2025). The company now projects core-basis revenue to be JPY 2,030,000 million, an increase of JPY 100,000 million (5.2%) from the previous forecast. Core operating profit is expected to reach JPY 490,000 million, up JPY 80,000 million (19.5%), and core profit for the year is projected at JPY 365,000 million, an increase of JPY 61,000 million (20.1%). Basic core earnings per share are now estimated at JPY 203.79.

The upward revision is attributed to the strong growth of strategic brands, including VYLOY, PADCEV, and XTANDI, which have seen increased sales across all regions. Additionally, cost optimization initiatives under the company-wide "Sustainable Margin Transformation" program have contributed positively to the improved outlook. For the first six months of FY2025, revenue increased by 10.1% year-on-year to JPY 1,030,114 million, with core operating profit rising by 54.4% to JPY 282,632 million.

On a full-basis, Astellas Pharma anticipates revenue of JPY 2,030,000 million and operating profit of JPY 240,000 million, a substantial increase from the initial JPY 160,000 million. Profit before tax is revised to JPY 230,000 million from JPY 150,000 million, and profit for the year is expected to be JPY 180,000 million, up from JPY 130,000 million. Basic earnings per share on a full-basis are projected at JPY 100.50, an increase of JPY 27.89. The company's assumed exchange rates for FY2025 are JPY 145/US$ and JPY 170/€.